Biotech Stocks
Biotechnology companies developing breakthrough drugs, gene therapies, and medical innovations. Binary outcomes with blockbuster upside potential.
200 stocks
Updated Sep 23, 2026
$1.97T
Total Market Cap
42.1
Avg P/E Ratio
+0.59%
Avg Daily Change
$1.30 – $803.90
Price Range
Biotech stocks represent companies developing drugs, therapies, and medical technologies using biological processes. The sector ranges from pre-revenue startups with experimental treatments in clinical trials to established companies with approved products generating billions in annual revenue.
Biotech investing is inherently binary and event-driven. Clinical trial results, FDA approvals, and patent expirations can cause massive overnight price moves in either direction. Major biotech companies include Amgen, Gilead Sciences, Regeneron, and Vertex Pharmaceuticals, while the small-cap space is filled with hundreds of companies betting on single drug candidates.
The sector has benefited from advances in gene therapy, mRNA technology, and AI-driven drug discovery that are accelerating the development pipeline. This list tracks biotech companies on U.S. exchanges with prices, P/E ratios, and market caps updated daily.
| # | Symbol | Name | Price | Change % | P/E | Market Cap |
|---|---|---|---|---|---|---|
| 1 | ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| 2 | AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| 3 | GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| 4 | VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| 5 | REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| 6 | MRNA | Moderna Inc | $182.56 | +5.56% | — | 63.11B |
| 7 | NTRA | Natera Inc | $390.90 | +5.47% | — | 52.80B |
| 8 | RVMD | Revolution Medicines Inc | $192.86 | +0.05% | — | 42.21B |
| 9 | BIIB | Biogen Inc | $225.36 | +2.87% | 38.8 | 32.37B |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |
| 11 | ROIV | Roivant Sciences Ltd | $38.22 | -1.97% | — | 28.53B |
| 12 | INSM | Insmed Inc | $120.82 | -0.15% | — | 26.21B |
| 13 | INCY | Incyte Corp | $126.93 | +1.83% | 16.0 | 25.87B |
| 14 | UTHR | United Therapeutics Corp | $497.59 | +0.91% | 16.2 | 21.24B |
| 15 | EXAS | Exact Sciences Corp | $104.91 | +0.95% | — | 20.03B |
| 16 | NBIX | Neurocrine Biosciences Inc | $142.25 | -1.19% | 21.9 | 15.43B |
| 17 | EXEL | Exelixis Inc | $58.15 | +1.63% | 16.8 | 14.49B |
| 18 | SMMT | Summit Therapeutics Inc | $17.12 | +1.30% | — | 14.14B |
| 19 | BBIO | Bridgebio Pharma Inc | $69.23 | +3.98% | — | 13.16B |
| 20 | HALO | Halozyme Therapeutics Inc | $115.13 | +3.30% | 30.7 | 12.70B |
| 21 | BMRN | Biomarin Pharmaceutical Inc | $63.37 | -1.08% | 172.6 | 12.60B |
| 22 | MDGL | Madrigal Pharmaceuticals Inc | $518.83 | -0.60% | — | 12.35B |
| 23 | APGE | Apogee Therapeutics Inc | $135.07 | -0.01% | — | 10.22B |
| 24 | KRYS | Krystal Biotech Inc | $350.88 | +5.10% | 41.3 | 9.97B |
| 25 | KYMR | Kymera Therapeutics Inc | $122.06 | +3.73% | — | 9.85B |
| 26 | NUVL | Nuvalent Inc-A | $123.96 | +0.02% | — | 9.79B |
| 27 | CYTK | Cytokinetics Inc | $67.59 | +0.04% | — | 9.65B |
| 28 | TWST | Twist Bioscience Corp | $164.60 | -0.74% | — | 9.42B |
| 29 | PTGX | Protagonist Therapeutics Inc | $145.07 | +0.06% | 112.2 | 9.30B |
| 30 | ARWR | Arrowhead Pharmaceuticals In | $71.86 | +4.46% | — | 9.29B |
| 31 | PCVX | Vaxcyte Inc | $59.02 | +0.17% | — | 8.98B |
| 32 | CAI | Caris Life Sciences Inc | $31.47 | +2.68% | 83.9 | 8.82B |
| 33 | TGTX | Tg Therapeutics Inc | $58.11 | +1.66% | 20.0 | 8.81B |
| 34 | IBRX | Immunitybio Inc | $9.29 | +9.94% | — | 8.63B |
| 35 | PRAX | Praxis Precision Medicines I | $300.65 | +0.60% | — | 8.52B |
| 36 | SYRE | Spyre Therapeutics Inc | $91.97 | -0.07% | — | 8.17B |
| 37 | IMVT | Immunovant Inc | $37.29 | +0.30% | — | 7.51B |
| 38 | IONS | Ionis Pharmaceuticals Inc | $45.75 | +1.89% | — | 7.45B |
| 39 | ALKS | Alkermes Plc | $43.29 | -2.01% | 111.3 | 7.36B |
| 40 | RYTM | Rhythm Pharmaceuticals Inc | $99.27 | +0.45% | — | 6.82B |
| 41 | ACLX | Arcellx Inc | $115.07 | +0.00% | — | 6.73B |
| 42 | CGON | Cg Oncology Inc | $77.74 | -0.65% | — | 6.61B |
| 43 | MIRM | Mirum Pharmaceuticals Inc | $91.39 | -0.66% | — | 6.42B |
| 44 | ORKA | Oruka Therapeutics Inc | $94.96 | -2.83% | — | 6.29B |
| 45 | KNSA | Kiniksa Pharmaceuticals Inte | $78.00 | -0.17% | 76.7 | 6.19B |
| 46 | TVTX | Travere Therapeutics Inc | $62.76 | -3.06% | — | 6.07B |
| 47 | SRRK | Scholar Rock Holding Corp | $51.19 | +6.29% | — | 5.97B |
| 48 | COGT | Cogent Biosciences Inc | $32.63 | +1.97% | — | 5.76B |
| 49 | ERAS | Erasca Inc | $15.55 | +3.39% | — | 5.68B |
| 50 | XENE | Xenon Pharmaceuticals Inc | $39.09 | +0.26% | — | 5.68B |
| 51 | DNTH | Dianthus Therapeutics Inc | $98.35 | +1.95% | — | 5.66B |
| 52 | PTCT | Ptc Therapeutics Inc | $65.96 | +1.07% | — | 5.57B |
| 53 | CRSP | Crispr Therapeutics Ag | $59.03 | +1.20% | — | 5.54B |
| 54 | APLS | Apellis Pharmaceuticals Inc | $41.03 | -0.07% | 39.4 | 5.25B |
| 55 | ACAD | Acadia Pharmaceuticals Inc | $26.41 | +0.06% | 12.2 | 4.65B |
| 56 | FOLD | Amicus Therapeutics Inc | $14.49 | +0.00% | — | 4.55B |
| 57 | IOVA | Iovance Biotherapeutics Inc | $10.63 | -0.09% | — | 4.54B |
| 58 | RLAY | Relay Therapeutics Inc | $19.07 | -1.45% | — | 4.21B |
| 59 | CELC | Celcuity Inc | $84.10 | +0.12% | — | 4.05B |
| 60 | TNGX | Tango Therapeutics Inc | $21.75 | -7.41% | — | 3.96B |
| 61 | CPRX | Catalyst Pharmaceuticals Inc | $31.49 | +0.03% | 17.4 | 3.85B |
| 62 | IDYA | Ideaya Biosciences Inc | $39.71 | +2.19% | — | 3.63B |
| 63 | GRAL | Grail Inc | $108.52 | +0.51% | — | 3.61B |
| 64 | VKTX | Viking Therapeutics Inc | $40.85 | +35.67% | — | 3.50B |
| 65 | DYN | Dyne Therapeutics Inc | $17.11 | -5.26% | — | 3.37B |
| 66 | ARQT | Arcutis Biotherapeutics Inc | $27.78 | +7.01% | 116.6 | 3.33B |
| 67 | RCUS | Arcus Biosciences Inc | $25.24 | -1.17% | — | 3.25B |
| 68 | VCYT | Veracyte Inc | $43.36 | +4.43% | 28.3 | 3.23B |
| 69 | DNLI | Denali Therapeutics Inc | $21.60 | +5.52% | — | 3.22B |
| 70 | CLDX | Celldex Therapeutics Inc | $38.24 | -1.90% | — | 3.06B |
| 71 | QURE | Uniqure Nv | $44.00 | -0.20% | — | 3.06B |
| 72 | PURR | Hyperliquid Strategies | $14.09 | +9.82% | — | 3.03B |
| 73 | PGEN | Precigen Inc | $7.92 | +0.38% | — | 2.82B |
| 74 | CDNA | Caredx Inc | $56.90 | +0.73% | 25.3 | 2.81B |
| 75 | SLNO | Soleno Therapeutics Inc | $53.01 | +0.00% | 28.8 | 2.76B |
| 76 | IMNM | Immunome Inc | $25.75 | +2.71% | — | 2.72B |
| 77 | NAMS | Newamsterdam Pharma Co Nv | $23.32 | +3.28% | — | 2.67B |
| 78 | IRON | Disc Medicine Inc | $68.48 | -0.01% | — | 2.66B |
| 79 | NRIX | Nurix Therapeutics Inc | $25.44 | -0.24% | — | 2.61B |
| 80 | BEAM | Beam Therapeutics Inc | $24.95 | +1.14% | — | 2.55B |
| 81 | VERA | Vera Therapeutics Inc | $36.26 | +5.87% | — | 2.46B |
| 82 | MLYS | Mineralys Therapeutics Inc | $28.02 | +0.14% | — | 2.45B |
| 83 | VRDN | Viridian Therapeutics Inc | $22.12 | +2.50% | — | 2.41B |
| 84 | SLS | Sellas Life Sciences Group I | $11.49 | -0.35% | — | 2.33B |
| 85 | AUPH | Aurinia Pharmaceuticals Inc | $16.67 | +0.36% | 7.2 | 2.26B |
| 86 | DAWN | Day One Biopharmaceuticals I | $21.53 | +0.00% | — | 2.22B |
| 87 | PVLA | Palvella Therapeutics Inc | $150.56 | -2.44% | — | 2.22B |
| 88 | BCRX | Biocryst Pharmaceuticals Inc | $8.68 | -0.23% | — | 2.22B |
| 89 | SRPT | Sarepta Therapeutics Inc | $20.48 | +1.69% | — | 2.18B |
| 90 | URGN | Urogen Pharma Ltd | $41.99 | -1.80% | — | 2.15B |
| 91 | ALVO | Alvotech Sa | $5.86 | +0.34% | — | 2.09B |
| 92 | BHVN | Biohaven Ltd | $13.62 | -1.94% | — | 2.07B |
| 93 | KOD | Kodiak Sciences Inc | $33.70 | -0.30% | — | 2.06B |
| 94 | VCEL | Vericel Corp | $39.55 | -1.17% | 84.1 | 2.04B |
| 95 | ZBIO | Zenas Biopharma Inc | $33.05 | +1.54% | — | 2.03B |
| 96 | ADMA | Adma Biologics Inc | $9.81 | +3.21% | 11.8 | 2.00B |
| 97 | AGIO | Agios Pharmaceuticals Inc | $34.85 | -0.34% | — | 2.00B |
| 98 | RXRX | Recursion Pharmaceuticals-A | $4.05 | +2.02% | — | 1.96B |
| 99 | STOK | Stoke Therapeutics Inc | $28.05 | -1.34% | — | 1.87B |
| 100 | ZYME | Zymeworks Inc | $26.81 | +0.90% | — | 1.86B |
Related ETFs
Exchange-traded funds that provide diversified exposure to the biotech stocks sector.
IBB
iShares
0.44% ER
iShares Biotechnology ETF
Tracks the Nasdaq Biotechnology Index. Market-cap weighted with large-cap biotech dominance.
XBI
SPDR
0.35% ER
SPDR S&P Biotech ETF
Equal-weighted biotech ETF. Gives small-cap biotech companies equal weight with giants like Amgen and Gilead.
ARKG
ARK Invest
0.75% ER
ARK Genomic Revolution ETF
Actively managed fund focused on genomics, gene editing (CRISPR), and molecular diagnostics companies.
Frequently Asked Questions
What are biotech stocks?
Biotech stocks are shares in companies that develop medical products using biological and genetic technologies. They range from large-cap leaders like Amgen (AMGN), Gilead Sciences (GILD), Regeneron (REGN), and Vertex Pharmaceuticals to small-cap companies with experimental drugs in clinical trials. Unlike traditional pharma, biotech companies focus on innovative biological therapies including gene editing, immunotherapy, and mRNA technology.
Are biotech stocks risky?
Biotech stocks are among the most volatile in the market. Small-cap biotechs can gain or lose 50% or more in a single day based on clinical trial results. Even large-cap biotechs face risks from patent cliffs and pipeline failures. The FDA approval process is lengthy and uncertain — roughly 90% of drugs entering clinical trials never reach the market. Diversification across multiple biotech names is essential to manage the high rate of individual failures.
What is an FDA approval and why does it matter?
FDA approval is the regulatory green light allowing a drug to be marketed and sold in the United States. The process involves three phases of clinical trials testing safety and efficacy, followed by an NDA or BLA review. An FDA approval can send a small biotech stock up 100% or more in a day, while a rejection or clinical failure can cause similar declines. The PDUFA date is the FDA's deadline for a decision and is closely watched by investors.
How to invest in biotech stocks?
For broad exposure with lower risk, consider biotech ETFs like the iShares Biotechnology ETF (IBB) or the SPDR S&P Biotech ETF (XBI). Individual stock investors should focus on companies with diversified pipelines, approved products, or late-stage clinical programs with strong data. Avoid betting heavily on single pre-revenue biotechs unless you understand the science. Position sizing is critical — limit individual biotech positions to manage binary risk.
What is the difference between biotech and pharma?
Biotech companies use biological processes to develop drugs — think proteins, antibodies, gene therapies, and mRNA. Pharma companies traditionally focus on chemical-based drugs (small molecules). In practice, the line has blurred as large pharma companies like Pfizer and Johnson & Johnson increasingly develop biological products. Biotech companies tend to be more innovation-driven and volatile, while pharma companies offer more stable earnings and dividends.
What are clinical trial phases?
Phase 1 tests safety in a small group (20-100 people). Phase 2 evaluates efficacy and side effects in a larger group (100-300). Phase 3 confirms effectiveness in large-scale trials (1,000-5,000+ patients) and is required for FDA submission. Each phase takes 1-3 years. Success rates improve at each stage: roughly 70% of drugs pass Phase 1, 33% pass Phase 2, and 25-30% pass Phase 3. Phase 3 results have the biggest impact on stock prices.
What is a patent cliff in biotech?
A patent cliff occurs when a drug's patent protection expires, allowing generic or biosimilar competitors to enter the market. This can cause revenue to drop 50-90% for that drug within a few years. Companies must replace expiring product revenue with new drugs from their pipeline. Major patent cliffs are well-known years in advance and are a key risk factor when evaluating biotech and pharma stocks.
What is gene therapy and CRISPR?
Gene therapy treats diseases by modifying a patient's genetic material, potentially offering one-time cures for conditions that previously required lifelong treatment. CRISPR-Cas9 is a revolutionary gene-editing tool that allows precise modifications to DNA. Companies like CRISPR Therapeutics, Intellia, and Editas Medicine are developing CRISPR-based treatments. The FDA approved the first CRISPR therapy in 2023, marking a milestone for the technology.
More Stock Lists
🩺
Healthcare & Biotech Stocks
Pharma giants, biotech innovators, and healthcare providers. Defensive plays with blockbuster drug upside.
→
🌱
Growth Stocks
Companies growing revenue at 10%+ per year with $1B+ market cap. The compounders that could become tomorrow's mega-caps.
→
¢
Penny Stocks
Stocks trading under $5 per share with at least $50M market cap. High-risk, high-reward territory for speculative traders.
→
▪
Small-Cap Stocks
Under-the-radar companies valued between $300M and $2B. Higher risk, higher reward — where multi-baggers are born.
→
⇅
Most Volatile Stocks
Stocks with the widest 52-week trading range relative to their current price. High beta names that swing hard in both directions.
→
🔥
Unprofitable Large Caps
Companies valued over $1B that are still burning cash. Pre-profit growth stories, turnaround plays, or value traps — proceed with caution.
→